Literature DB >> 7602128

Characterization of a soluble, oligomeric HIV-1 gp160 protein as a potential immunogen.

T C VanCott1, S C Veit, V Kalyanaraman, P Earl, D L Birx.   

Abstract

We have assessed the oligomeric structure and antigenic properties of an affinity purified gp160 protein (oligo-gp160) using biosensor technology. Sucrose gradient purification analysis identified the existence of tetrameric, dimeric and monomeric forms of the protein. Reactivity to a broad panel of monoclonal antibodies specific for oligomeric gp160, discontinuous epitopes within monomeric gp120 and several linear epitopes within gp120 (V3) and gp41 was demonstrated. International sera from several countries, where HIV-1 clades A-F are prevalent, including type O from Cameroon, were reactive with oligo-gp160 indicating conserved antigenic epitopes. Enhanced immunologic reactivity per gp160 molecule was obtained with oligo-gp160 as compared to other current HIV-1(IIIB) subunit monomeric envelope gp120/gp160 immunogens suggesting higher HIV-1 envelope protein mimicry. HIV-1 antibodies from sera during acute HIV-1 infection were detectable by oligo-gp160 prior to detection with either a recombinant, monomeric gp120 protein or several commercial HIV-1 screening kits suggesting antibodies sensitive to oligomeric gp160 structure may be present earlier in infection. The oligomeric nature of this gp160 protein preparation and high reactivity with divergent mAbs and HIV-1 sera support the use of this protein as an HIV-1 immunogen.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7602128     DOI: 10.1016/0022-1759(95)00038-c

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  13 in total

1.  Immunotyping of human immunodeficiency virus type 1 (HIV): an approach to immunologic classification of HIV.

Authors:  S Zolla-Pazner; M K Gorny; P N Nyambi; T C VanCott; A Nádas
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.

Authors:  F Verrier; S Burda; R Belshe; A M Duliege; J L Excler; M Klein; S Zolla-Pazner
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.

Authors:  J R Mascola; M K Louder; T C VanCott; C V Sapan; J S Lambert; L R Muenz; B Bunow; D L Birx; M L Robb
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  The ferritin-like protein Frm is a target for the humoral immune response to Listeria monocytogenes and is required for efficient bacterial survival.

Authors:  Walid Mohamed; Ayub Darji; Eugen Domann; Emilia Chiancone; Trinad Chakraborty
Journal:  Mol Genet Genomics       Date:  2006-03-10       Impact factor: 3.291

5.  Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.

Authors:  P L Earl; W Sugiura; D C Montefiori; C C Broder; S A Lee; C Wild; J Lifson; B Moss
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

6.  Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160.

Authors:  T C VanCott; J R Mascola; R W Kaminski; V Kalyanaraman; P L Hallberg; P R Burnett; J T Ulrich; D J Rechtman; D L Birx
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

7.  Antigenicity and immunogenicity of a trimeric envelope protein from an Indian clade C HIV-1 isolate.

Authors:  Rangasamy Sneha Priya; Menon Veena; Irene Kalisz; Stephen Whitney; Dhopeshwarkar Priyanka; Celia C LaBranche; Mullapudi Sri Teja; David C Montefiori; Ranajit Pal; Sundarasamy Mahalingam; Vaniambadi S Kalyanaraman
Journal:  J Biol Chem       Date:  2015-02-17       Impact factor: 5.157

8.  Limited protection from a pathogenic chimeric simian-human immunodeficiency virus challenge following immunization with attenuated simian immunodeficiency virus.

Authors:  M G Lewis; J Yalley-Ogunro; J J Greenhouse; T P Brennan; J B Jiang; T C VanCott; Y Lu; G A Eddy; D L Birx
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

9.  A simple one-step method for the preparation of HIV-1 envelope glycoprotein immunogens based on a CD4 mimic peptide.

Authors:  Grégoire Martin; Yide Sun; Bernadette Heyd; Olivier Combes; Jeffrey B Ulmer; Anne Descours; Susan W Barnett; Indresh K Srivastava; Loïc Martin
Journal:  Virology       Date:  2008-10-02       Impact factor: 3.616

10.  Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140.

Authors:  N M Stamatos; J R Mascola; V S Kalyanaraman; M K Louder; L M Frampton; D L Birx; T C VanCott
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.